



European Reference Network: Clinical Practice Guidelines And Clinical Decision Support Tools

September 28th 2020

Methodological Handbooks & Toolkit
for Clinical Practice Guidelines and
Clinical Decision Support Tools for Rare
or Low Prevalence and Complex Diseases
Introductory document

Prepared by:
Aragon Health Sciences Institute (IACS)



LEGAL NOTICE

This report was produced under the third Health Programme (2014-2020). The content of this report represents the views of the contractor and is its sole responsibility; it can in no way be taken to reflect the views of the European Commission or any other body of the European Union. The European Commission do not guarantee the accuracy of the data included in this report, nor do they accept responsibility for any use made by third parties thereof.

More information on the European Union and on European Reference Networks is available on the Internet (<http://www.europa.eu>) (https://ec.europa.eu/health/ern_en)

© European Union, 2020

Reproduction is authorised provided the source is acknowledged.

EUROPEAN COMMISSION

Directorate-General for Health and Food Safety

Directorate B — Health systems, medical products and innovation

Unit B.3 — Digital Health, European Reference Networks

Contact: Enrique Terol

E-mail: enrique.terol@ec.europa.eu

European Commission B-1049 Brussels



Authors: coordination team (in alphabetical order)

María Bono Vega, BSc in Biochemistry

Aragon Health Sciences Institute (IACS, Spain)

Patricia Gavín Benavent, MD, PhD

Aragon Health Sciences Institute (IACS, Spain)

María Soledad Isern de Val, BSc in Biochemistry, PhD

Aragon Health Sciences Institute (IACS, Spain)

Celia Muñoz Fernández, BA in Economics

Aragon Health Sciences Institute (IACS, Spain)

Lucía Prieto Remón, BA in Business and Marketing

Aragon Health Sciences Institute (IACS, Spain)

Authors: Information Specialist

María Pilar Blas Diez, Information Specialist

Aragon Health Sciences Institute (IACS, Spain)

Authors: internal reviewers (in alphabetical order)

María Pilar Calvo Pérez, MD

Aragon Health Sciences Institute (IACS, Spain)

Sandra García Armesto, MD, PhD

Aragon Health Sciences Institute (IACS, Spain)

Authors: collaborators (in alphabetical order)

Juan Ignacio Martín Sánchez, MD

Aragon Health Sciences Institute (IACS, Spain)

Silvia Vázquez Fernández del Pozo, MD, PhD

Aragon Health Sciences Institute (IACS, Spain)

María José Vicente Edo, BSc in Nursing

Aragon Health Sciences Institute (IACS, Spain)

Authors: Administrative assistance

María Esther García Pomar, Administrative officer

Aragon Health Sciences Institute (IACS, Spain)



Contact info:

FPS-AETSA
ERNGuideLinesCoordination.fps@juntadeandalucia.es
Fundación Pública Andaluza Progreso y Salud (FPS)
Avd. Américo Vespucio 15, Edificio S-2
C.P. 41092 Seville, Spain
+34 955 006636





TABLE OF CONTENTS

Background	7
1.1 Work Package B: Methodologies for CPGs and CDSTs for Rare Diseases	7
Scope	8
2.1 Aim of the Toolkit	8
2.1.1 What this Toolkit is	8
2.1.2 What this Toolkit is not	8
2.2 Who is the Toolkit for	8
2.3 Clinical Practice Guidelines (CPGs) and Clinical Decision Support Tools (CDSTs) covered in this Toolkit	8
Overview of the Methods of the Handbooks and Tools	11
Structure of the Toolkit	12
Content of the Toolkit: Handbooks, Tools and Other Resources	13
5.1 Prioritisation	13
5.2 Appraisal	13
5.3 Adoption and Adaptation	14
5.4 Development	14
5.5 Implementation	14
Bibliography	15





ABBREVIATIONS

AETSA	Andalusian Health Technology Assessment Department
AGREE II	Appraisal of Guidelines for Research & Evaluation II
CDSTs	Clinical Decision Support Tools
CPGs	Clinical Practice Guidelines
ERN	European Reference Network
EU	European Union
FPS	Fundación Pública Andaluza Progreso y Salud
G-I-N	Guidelines International Network
GRADE	Grading of Recommendations Assessment, Development and Evaluation





01.

BACKGROUND

There are a number of challenges surrounding the development of CPG and CDST for rare diseases. One of the most relevant barrier is the lack of high-quality evidence, in which the foremost methodological frameworks like GRADE rely on 1.

Therefore, there is a need for specific methodological approaches that can provide reliable and useful Clinical Practice Guidelines (CPGs) and Clinical Decision Support Tools (CDST) for rare diseases. The project also aims to provide a common methodology, in order to harmonise the elaboration process of CDST and CPGs.





02.

SCOPE

2.1 | Aim of the Toolkit

This toolkit aims at providing methodological guidance and foster skill development for the prioritisation, appraisal, adaptation, adoption, development and implementation of CPGs and CDSTs for rare diseases in the context of ERNs.

2.1.1 / *What this Toolkit is*

This toolkit is a practical set of methodological handbooks and tools for the prioritisation, appraisal, adaptation, development and implementation of CPGs and CDSTs for rare diseases developed for the ERNs and based on existing methodologies relevant and applicable for rare diseases, as well as general methodological approaches with a wide international consensus.

2.1.2 / *What this Toolkit is not*

This toolkit is not a methodological approach developed de novo for the prioritisation, appraisal, adaptation, development and implementation of CPGs and CDSTs for rare diseases.

2.2 | Who is the Toolkit for

The target audience of this toolkit are the ERNs, but it could also be useful for any professional working within the scope of rare diseases who would like to develop new or use existing evidence-based CPGs or CDSTs.

2.3 | Clinical Practice Guidelines (CPGs) and Clinical Decision Support Tools (CDSTs) covered in this Toolkit

This toolkit provides methodology for the appraisal, adaptation, adoption, development and implementation of the CPGs and CDSTs defined in a previous TENDER *Taxonomy and templates for the European Reference Networks documents* (SANTE/2017/B3/083). These CPGs and CDSTs are the following:

Clinical Practice Guidelines

Clinical practice guidelines (CPGs) are systematically developed statements that include

recommendations, intended to optimise patient care, that are informed by a systematic review of evidence and an assessment of the benefit and harms of alternative care options ². The level of evidence needs to be stated.

Clinical Consensus Statements

Clinical consensus statements reflect opinions drafted by subject matter experts for which consensus is sought using explicit methodology to identify areas of agreement and disagreement. In contrast to clinical practice guidelines, which are based primarily on high-level evidence, clinical consensus statements are more applicable to situations where evidence is limited or lacking, yet there are still opportunities to reduce uncertainty and improve quality of care ^{3,4}. It offers specific recommendations on a topic. It does not give specific algorithms.

Evidence Reports

Evidence reports are systematic reviews that summarises the best available evidence on a topic. Evidence reports are generally used by clinical professional organisations to support the development of clinical practice guidelines or by policy makers to inform their programme planning and research priorities ⁵.

Diagnostic, Monitoring and Therapy Pathways

Diagnostic, monitoring and therapy pathways are multidisciplinary management tools which describe the procedure for the care and treatment of a disease, condition or complex procedure. Their aim is to improve the care and management of patients, while enhancing the coordination of healthcare around the patient. They include the “red flags” that may lead to suspicion on the disease, condition or complex procedure, how to reach a definite diagnosis and the management and follow-up recommendations, establishing the sequences for each action and defining the responsibilities of the different professionals who will intervene in the diagnostic, monitoring and therapy pathway ⁶.

Evidence-based Protocols

Evidence-based protocols are an agreed detailed framework outlining in chronological order the care procedures that will be performed in a designated area of practice. Evidence-based protocols state what should be done, and how it should be done. It is adapted to the health care environment and the available resources ⁷. In order to facilitate its use, evidence-based protocols usually include a flowchart in which the steps to be taken and the agents involved in the evidence-based protocols' workflow are clearly depicted.

Do's and Don'ts Factsheets for Diseases

Do's and Don'ts Factsheets are tools that provide advice that needs to be considered when assisting patients with specific rare diseases, conditions or in need of complex procedures. These documents aim to assist patients, caregivers and the medical community in knowing the basic do's and don'ts of common and emergency situations (e.g., delivery, physical activity, anaesthesia, stroke, surgery) ⁸. Do's and don'ts factsheets can be based on existing CPGs or CDSTs recommendations (i.e., one or more documents), or they may consist of a stand-alone product developed from scratch by a panel of experts making recommendations by consensus (e.g., specialists on rare diseases who collect established and well-known clinical practice information about patient management, as a guide to other specialists involved in the treatment of people living with a rare disease).

Quality Measures

Quality measures are tools that quantify healthcare processes, outcomes, patient perceptions, and organizational structure and/or systems. These instruments provide healthcare professionals and policy makers with information associated with healthcare performance and the extent to which

high quality health care is being provided. There are three types of quality measures/indicators (structure, process, and outcome), as framed in the Donabedian model ^{9,10}.

There are different frameworks for classifying quality measures. The main models structure measurements based on six aims for healthcare systems ¹¹, which are effective, safe, efficient, patient-centered, equitable, and timely care according to the Institute of Medicine ¹² approach.

Patient Information Booklets

Document that provides condition-specific information in lay language, to inform patients on best medical practice in an informative and accessible way ^{13,14}. Patient information booklets can be based on a CPG, a CDST or consist of a stand-alone product that provides general information for the patient.



03.

OVERVIEW OF THE METHODS OF THE HANDBOOKS AND TOOLS

The work included in this Methodological Handbooks and Toolkit has been developed during the first six months, from January to June 2020. It started with an exhaustive analysis of the state of the art on methodologies for CPGs and CDSTs for rare diseases, which was reviewed by experts from the ERNs and institutions with methodological expertise. This was conducted from January to March 2020 and summarised a Report on the Literature Review and Expert Consultation . These findings were incorporated in the development of this Methodological Handbooks and Toolkit and has been developed from March 2020-June 2020.

In addition to the methodologies specific for rare diseases retrieved in the Report on the Literature Review and Expert Consultation, other methodological approaches with a wide international consensus have been considered and used for the development of these Methodological Handbooks and for the Toolkit. These include, for example, the Guidelines International Network (G-I-N) standards for guideline development ¹⁵, the Appraisal of Guidelines for Research & Evaluation II (AGREE II) ¹⁶, Grading of Recommendations Assessment, Development and Evaluation (GRADE) ¹ and the ADAPTE methodology for guideline adaptation ^{17, 18}

Furthermore, the ERNs and institutions with methodological expertise have participated in a consultation made by means of online surveys about the prioritisation of conditions that require CPGs and CDSTs the appraisal of CPGs and CDSTs for rare diseases.

More detailed information on the development of each handbook and tool can be found in the respective documents.




04.

STRUCTURE OF THE TOOLKIT

The structure of the toolkit follows the subsequent milestones for the use of CPGs and CDSTs, from the prioritisation of conditions that require CPGs or CDSTs to the implementation of the CPGs or CDSTs. Figure 1 shows the main milestones of this process.

Figure 1. Milestones for the use of CPGs and CDSTs.





05.

CONTENT OF THE TOOLKIT: HANDBOOKS, TOOLS AND OTHER RESOURCES

5.1 | Prioritisation

Handbook #1: Prioritisation of the rare diseases that require CPGs or CDSTs

This handbook includes a detailed explanation of the prioritisation criteria and of the prioritisation process, including the use of the prioritisation tool.

Tool #1: Prioritisation Tool of Conditions that Require CPGs or CDSTs

This tool provides a prioritised list of conditions and a heat map, as a result of the assessment of the relevance of a pre-defined list of conditions for the development of CPGs or CDSTs.

5.2 | Appraisal

Handbook #2: Appraisal of existing CPGs and CDSTs for rare diseases

This handbook includes a pragmatic assessment process of the methodological quality of CPGs, CDSTs and informative documents for rare diseases, including the use of the CPG and CDSTs appraisal tools.

Tool #2.1: Appraisal Tool for CPGs (AGREE II)

The tool for the quality assessment of CPG has been developed based on AGREE II instrument. It includes a set of templates aimed at facilitating the quality appraisal of CPGs and the subsequent discussion within the working group.

Tool #2.2: Appraisal Tool for CDSTs and informative documents

This tool presents the appraisal criteria for CDST and informative documents in a template to be completed, which helps to assess whether they meet the minimum quality requirements for their use.



5.3 | Adoption and Adaptation

Handbook #3: Adaptation and Adoption of CPGs and CDSTs

This handbook describes the elements that should be addressed in order to decide on whether a CPG or a CDST for rare diseases can be adopted or adapted and indicates the actions that must be followed to adopt and adapt a CPG and a CDST for rare diseases.

5.4 | Development

Handbooks #4 - 11: Handbooks for the Elaboration of CPGs and CDSTs for Rare Diseases

These handbooks explain the steps to develop a CPG or CDST for rare diseases, including the definition of the scope and purpose, the formulation of clinical questions and the search, selection, appraisal and synthesis of the scientific evidence, among others. There is a development handbook for CPGs and each CDSTs covered in this toolkit.

- ✓ Handbook #4: Methodology for the elaboration of CPGs for rare diseases
- ✓ Handbook #5: Methodology for the elaboration of Clinical Consensus Statements for rare diseases
- ✓ Handbook #6: Methodology for the elaboration of Evidence Reports for rare diseases
- ✓ Handbook #7: Methodology for the elaboration of Diagnostic, Monitoring and Therapy Pathways for rare diseases
- ✓ Handbook #8: Methodology for the elaboration of Evidence-based Protocols for rare diseases
- ✓ Handbook #9: Methodology for the elaboration of Do's and Don't's Factsheets for Diseases for rare diseases
- ✓ Handbook #10: Methodology for the elaboration of Quality Measures for rare diseases
- ✓ Handbook #11: Methodology for the elaboration of Patient Information Booklets for rare diseases

5.5 | Implementation

Handbook #12: Implementation and Evaluation of the Uptake of CPGs and CDSTs for rare diseases

This handbook provides the steps that have to be taken in order to implement a CPG or a CDST for rare diseases, including the selection of the CPG or CDST to implement, the planning of the implementation, analysis of the context, design of the interventions and methods to carry out their evaluation of the implementation and of the uptake of the CPG or CDST, development of the implementation roadmap and design of the continuous improvement mechanism.



06.

BIBLIOGRAPHY

1. Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. *J Clin Epidemiol*. 2011;64(4):383-94.
2. Institute of Medicine (US) Committee on Standards for Developing Trustworthy Clinical Practice Guidelines. *Clinical practice guidelines we can trust* [Internet]. Washington (DC): National Academies Press (US); 2011 [cited 15/06/2020]. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK209539/>.
3. Rosenfeld RM, Nnacheta LC, Corrigan MD. Clinical Consensus Statement Development Manual. *Otolaryngology--head and neck surgery: official journal of American Academy of Otolaryngology-Head and Neck Surgery*. 2015;153(2 Suppl):S1-s14.
4. Beighton D. Consensus Statements. *Caries Res*. 2017;51(5):I-II.
5. EPC Evidence-Based Reports. 2013 [cited 19/03/2020]. Available from: <https://www.ahrq.gov/research/findings/evidence-based-reports/index.html>.
6. GuíaSalud: Biblioteca de Guías de Práctica Clínica del Sistema Nacional de Salud [Internet]. 2019 [cited 23/06/2020]. Definiciones y tipología OPBES: Vías Clínicas. Available from: <https://portal.guiasalud.es/definiciones-tipologia-opbe/#1537695268615-b7f631b8-7a14>.
7. GuíaSalud: Biblioteca de Guías de Práctica Clínica del Sistema Nacional de Salud [Internet]. 2019 [cited 23/06/2020]. Definiciones y tipología OPBES: Protocolos. Available from: <https://portal.guiasalud.es/definiciones-tipologia-opbe/#1537695224514-45ead613-5807>.
8. VASCERN [Internet]. European Reference Network on Rare Multisystemic Vascular Diseases (VASCERN); [2019] [cited 19/03/2020]. VASCERN Do's and Don'ts factsheets for rare vascular disease patients facing frequent situations. Available from: <https://vascern.eu/what-we-do/dos-donts-factsheets-for-rare-vascular-disease-patients/>.
9. Donabedian A. *The definition of quality and approaches to its assessment*. Ann. Arbor, Mich.: Health Administration Press; 1980.
10. Agency for Healthcare Research and Quality [Internet]. Rockville, MD: AHRQ; 2015 [cited 23/06/2020]. Select Health Care Quality Measures for a Consumer Report. Available from: <https://www.ahrq.gov/talkingquality/measures/index.html>.
11. Centers for Medicare & Medicaid Services [Internet]. CMS; [cited 23/06/2020]. Quality Measures. Available from: <https://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment->



[Instruments/QualityMeasures#:~:text=Quality%20measures%20are%20tools%20that,quality%20goals%20for%20health%20care.](#)

12. Institute of Medicine Committee on Quality of Health Care in America. Crossing the Quality Chasm: A New Health System for the 21st Century. Washington (DC): National Academies Press (US). 2001.
13. European CHS Network. Central Hypoventilation Syndrome: Patient and Carer Information Booklet [Internet]. 2012 [cited 23/06/2020]. Available from: http://www.ichsnetwork.eu/upload/gaslini_ondine/gestionedocumentale/EU-CHS%20Patient%20Information%20Booklet_784_2550.pdf.
14. Keinki C, Zowalla R, Wiesner M, Koester MJ, Huebner J. Understandability of Patient Information Booklets for Patients with Cancer. J Cancer Educ. 2018;33(3):517-27.
15. Qaseem A, Forland F, Macbeth F, Ollenschlager G, Phillips S, van der Wees P, et al. Guidelines International Network: toward international standards for clinical practice guidelines. Ann Intern Med. 2012;156(7):525-31.
16. AGREE Next Steps Consortium. The Appraisal of Guidelines for Research and Evaluation (AGREE) II Instrument [Internet]. 2017 [cited 15/06/2020]. Available from: <https://www.agreetrust.org/>.
17. The ADAPTE Collaboration. The ADAPTE Process: Resource Toolkit for Guideline Adaptation.[Internet]. 2009 [cited 23/06/2020]. Available from: <http://www.g-i-n.net>.
18. Abdul-Khalek RA, Darzi AJ, Godah MW, Kilzar L, Lakis C, Agarwal A, et al. Methods used in adaptation of health-related guidelines: A systematic survey. J Glob Health. 2017;7(2):020412.



European
Reference
Networks



European
Reference
Networks

ERN
GUIDELINES